Company profile: Psomagen
1.1 - Company Overview
Company description
- Provider of genomics services for research, clinical, and direct-to-consumer applications, including whole genome sequencing, targeted sequencing, Illumina-compatible library runs as flow cell or lane units with full quality control and sample multiplexing, and genetic testing panels to identify gene, chromosome, or protein changes to help confirm or rule out genetic conditions and assess disease risk.
Products and services
- Genetic Testing Panels: Delivers multi-analyte panel screening to identify gene, chromosome, or protein changes, confirming or ruling out genetic conditions and assessing disease risk
- Targeted Sequencing: Architects region-specific sequencing assays to interrogate defined genomic loci for disease-related variants, inherited mutations, and gene editing events, providing detailed insights into targeted regions
- Whole Genome Sequencing (WGS): Executes genome-wide sequencing to catalog genetic variation across the entire genome, revealing pathogenic and risk-associated variants to power research and clinical diagnosis across diverse fields
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Psomagen
Aura Biosciences
HQ: United States
Website
- Description: Provider of virus-like drug conjugates (VDCs) using virus-like particles to target solid tumors by delivering cytotoxic drugs or nucleic acids. Develops Belzupacap Sarotalocan (Bel-sar) for first-line treatment of early-stage choroidal melanoma and other ocular oncology indications, with potential in choroidal metastasis, aiming to preserve vision and prevent metastatic disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aura Biosciences company profile →
CustomArray
HQ: United States
Website
- Description: Provider of oligonucleotide pool libraries to many of the world’s premier academic and industrial organizations for applications including synthetic biology, gene synthesis, CRISPR, targeted sequencing, complex DNA libraries, shRNA libraries, and DNA data storage.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CustomArray company profile →
Claritas Genomics
HQ: United States
Website
- Description: Provider of genomics solutions, established as a new venture through a partnership between Boston Children's Hospital and Life Technologies Corp.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Claritas Genomics company profile →
MaaT Pharma
HQ: France
Website
- Description: Provider of microbiome ecosystem therapies to restore patient–microbiome symbiosis and improve outcomes in cancers and GvHD. Offers MET-N and MET-C candidates, MaaT013 for acute GvHD, MaaT033 to improve survival post allo-HSCT, and MaaT03X to enhance response to immune checkpoint inhibitors in solid tumors, plus gutPrint, an AI platform for MET design, and cGMP manufacturing for standardized microbiome-based drug candidates.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MaaT Pharma company profile →
10x Genomics
HQ: United States
Website
- Description: Provider of an innovative genomics platform delivering spatial and single-cell multiomic solutions: Visium HD Spatial Gene Expression for whole transcriptome analysis at single cell-scale with continuous tissue coverage; Chromium Single Cell Gene Expression with multiomic options; Chromium Single Cell Immune Profiling with gene expression, cell surface proteins, and full-length paired BCR/TCR; and Xenium In Situ for subcellular single-molecule RNA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full 10x Genomics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Psomagen
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Psomagen
2.2 - Growth funds investing in similar companies to Psomagen
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Psomagen
4.2 - Public trading comparable groups for Psomagen
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →